AstraZeneca (AZN) plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq, the pharmaceutical giant ...
AstraZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England, research site, a company spokesperson has confirmed to Fierce Biotech. The pharma's pullback is ...